title: Role of consolidation therapy in transplant eligible multiple myeloma patients.
abstract: The role of high-dose therapy and autologous stem-cell transplantation (ASCT) in the treatment of multiple myeloma (MM) has continued to evolve in recent years. The novel agents thalidomide, bortezomib, and lenalidomide have been successfully incorporated into induction therapy in preparation for ASCT and are currently being investigated also as post-ASCT consolidation and maintenance therapy. Consolidation treatment is generally short term and aims to increase the frequency and depth of response obtained with the previous treatment phases, including novel agent-based induction therapy and ASCT. This review will focus on recent trials of novel agents as post-ASCT consolidation therapy, offering an overview of pros and cons of this new treatment strategy in the ASCT sequence for MM patients.
authors.affiliation: "Seràgnoli" Institute of Hematology, Bologna University School of Medicine, Italy. Electronic address: michele.cavo@unibo.it.
authors.forename: Michele
authors.initials: M
authors.lastname: Cavo
authors.forename: Annamaria
authors.initials: A
authors.lastname: Brioli
authors.forename: P
authors.initials: P
authors.lastname: Tacchetti
authors.forename: B A
authors.initials: BA
authors.lastname: Zannetti
authors.forename: K
authors.initials: K
authors.lastname: Mancuso
authors.forename: E
authors.initials: E
authors.lastname: Zamagni
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D060830:Consolidation Chemotherapy; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000628:therapy*; D011719:Pyrazines / Q000008:administration & dosage; D033581:Stem Cell Transplantation / Q000379:methods*; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D014182:Transplantation, Autologous / Q000379:methods; D016896:Treatment Outcome
chemical_list: D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide